Core Outcome Set for Melasma

Background
Clinical trials of melasma are difficult to compare due to variation in the outcomes reported.

Objective
The purpose of this study was to develop a core set of outcome domains to be assessed in all clinical trials of melasma.

Methods
Identification of outcomes was performed via a literature review. Thereafter, 2 rounds of Delphi surveys were conducted, followed by consensus meetings to determine which outcomes should be in the final core domain set.

Results
Seven core outcomes were recommended: relative intensity of representative area of pigmentation relative to baseline; color of dark spots; area and distribution of pigmentation; overall severity of melasma; patient satisfaction with treatment; quality of life; presence and severity of persistent versus transient treatment-related adverse events.

Limitations
Hormonal and intrinsic vascular factors were not included in the core outcome set due to limited feasibility and lack of routine measurement as outcomes in clinical trials and in clinical practice. Additionally, there were very few Hispanic individuals in the Delphi group, although melasma is very common in Hispanic individuals.

Conclusion
A core outcome set has been developed for melasma trials. Routine use of this may improve comparability and pooling of data emanating from such trials.

Aim

The purpose of this COS is to better detect clinical onset of melasma, and measure change in melasma associated with therapy.

Contributors

McKenzie A Dirr, Areeba Ahmed, Daniel I Schlessinger, Sabrina S Smith, Rachel E Christensen, Thanvi Gullapalli, Joycie Chang, Doroteja Dragovic, Vanessa J Lazaro-Camp, Jennifer C Tang, Noor Anvery, Jochen Schmitt, Jamie J Kirkham, Ian A Maher, Joseph F Sobanko, Todd V Cartee, Brian A Cahn, Emily Poon, Elizabeth Zhang, Murad Alam; Melasma Core Outcome Set Working Group (Melasma COS Working Group)

Publication

Journal: Journal of the American Academy of Dermatology
Volume: 95
Issue: 3
Pages: 716 - 723
Year: 2026
DOI: https://doi.org/10.1016/j.jaad.2026.04.1942

Further Study Information

Current Stage: Completed
Date: July 2015 - March 2026
Funding source(s): Departmental research funds


Health Area

Disease Category: Skin

Disease Name: Melasma

Target Population

Age Range: 18 - 85

Sex: Either

Nature of Intervention: Any

Stakeholders Involved

- Clinical experts
- Consumers (patients)
- Families
- Governmental agencies
- Methodologists
- Pharmaceutical industry representatives

Study Type

- COS for clinical trials or clinical research
- COS for practice

Method(s)

- Consensus conference
- Delphi process
- Focus group(s)
- Interview
- Nominal group technique (NGT)
- Systematic review

Systematic review of outcomes followed by involvement of key stakeholders using interview/focus group/Delphi process. Consolidation of results using NGT and consensus conference.

Linked Studies

    No related studies


Related Links